Print
Email
Print Edition StoriesTuesday, February 26, 2008
Caliper license deal ends AntiCancer patent suit
Caliper Life Sciences Inc. reports it has ended patent litigation between the scientific research products firm and AntiCancer Inc. via a cross-licensing deal.
The deal enables Hopkinton-based Caliper (Nasdaq: CALP) to sublicense fluorescent protein optical imaging technology belonging to AntiCancer to third parties, while allowing AntiCancer to sublicense Caliper's optical imaging patents to other entities, for use in the field of fluorescent protein imaging.
The deal calls for AntiCancer, a San Diego life sciences company, and Caliper to share revenue from the licenses to third parties. No other payments would be made in connection with the agreement, according to the life sciences firms.
Caliper, which provides instruments, reagents and software for life sciences research, reported a 2007 net loss of $24.1 million on revenue of $140.7 million. The life sciences firm employs 550 workers.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
